MK-940

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525659

CAS#: 5154-92-7

Description: MK-940 is a potential central nervous system agent and an anti-depressant.

Chemical Structure

img
MK-940
CAS# 5154-92-7
Instruction

Theoretical Analysis

MedKoo Cat#: 525659
Name: MK-940
CAS#: 5154-92-7
Chemical Formula: C23H23NO5
Exact Mass: 393.16
Molecular Weight: 393.432
Elemental Analysis: C, 70.21; H, 5.89; N, 3.56; O, 20.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MK940; MK 940; MK-940

IUPAC/Chemical Name: (Z)-4-(((5S,10S)-5-(3-(methylamino)propyl)-10,11-dihydro-5H-5,10-epoxydibenzo[a,d][7]annulen-11-yl)oxy)-4-oxobut-2-enoic acid

InChi Key: JZLSDHRLQHINSS-NHDOGELNSA-N

InChi Code: InChI=1S/C23H23NO5/c1-24-14-6-13-23-17-9-4-2-7-15(17)21(28-20(27)12-11-19(25)26)22(29-23)16-8-3-5-10-18(16)23/h2-5,7-12,21-22,24H,6,13-14H2,1H3,(H,25,26)/b12-11-/t21?,22-,23+/m0/s1

SMILES Code: CNCCC[C@@]1(O2)C3=CC=CC=C3C(OC(/C=C\C(O)=O)=O)[C@]2([H])C4=CC=CC=C14

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 393.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Verdurand M, Nguyen V, Stark D, Zahra D, Gregoire MC, Greguric I, Zavitsanou K. Comparison of Cannabinoid CB(1) Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [F]MK-9470. Int J Mol Imaging. 2011;2011:548123. doi: 10.1155/2011/548123. Epub 2011 Dec 11. PubMed PMID: 22187642; PubMed Central PMCID: PMC3236487.
2: Gannon P, Itil T, Keskiner A, Hsu B. Clinical and quantitative electroencephalographical effects of MK 940. Arzneimittelforschung. 1970 Jul;20(7):971-4. PubMed PMID: 4918922.
3: Amoozegar MA, Makhdoumi-Kakhki A, Mehrshad M, Fazeli SA, Spröer C, Ventosa A. Halorientalis persicus sp. nov., an extremely halophilic archaeon isolated from a salt lake and emended description of the genus Halorientalis. Int J Syst Evol Microbiol. 2014 Mar;64(Pt 3):940-4. doi: 10.1099/ijs.0.058164-0. Epub 2013 Dec 18. PubMed PMID: 24425819.
4: Finster KW, Cockell CS, Voytek MA, Gronstal AL, Kjeldsen KU. Description of Tessaracoccus profundi sp.nov., a deep-subsurface actinobacterium isolated from a Chesapeake impact crater drill core (940 m depth). Antonie Van Leeuwenhoek. 2009 Nov;96(4):515-26. doi: 10.1007/s10482-009-9367-y. Epub 2009 Aug 8. PubMed PMID: 19669589.
5: Xu M, Qiang F, Gao Y, Kang M, Wang M, Tao G, Gong W, Zhu H, Wu D, Zhang Z, Zhao Q. Evaluation of a novel functional single-nucleotide polymorphism (rs35010275 G>C) in MIR196A2 promoter region as a risk factor of gastric cancer in a Chinese population. Medicine (Baltimore). 2014 Nov;93(26):e173. doi: 10.1097/MD.0000000000000173. PubMed PMID: 25474430; PubMed Central PMCID: PMC4616385.
6: Ankermann T, Reisner A, Wiemann T, Koehler H, Krams M, Krause MF. Intrapulmonary application of a 5-lipoxygenase inhibitor using surfactant as a carrier reduces lung edema in a piglet model of airway lavage. Pediatr Pulmonol. 2006 May;41(5):452-62. PubMed PMID: 16547963.
7: Sommer C, Schomacher M, Berger C, Kuhnert K, Müller HD, Schwab S, Schäbitz WR. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006 Sep;112(3):277-86. Epub 2006 Jul 27. PubMed PMID: 16871404.
8: Qussi B, Suess WG. Investigation of the effect of various shellac coating compositions containing different water-soluble polymers on in vitro drug release. Drug Dev Ind Pharm. 2005 Jan;31(1):99-108. PubMed PMID: 15704861.
9: Melis MR, Succu S, Mascia MS, Argiolas A. Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection. Neurosci Lett. 2004 Apr 8;359(1-2):17-20. PubMed PMID: 15050701.
10: Carswell HV, Graham DI, Stone TW. Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: possible involvement of free radicals. J Neurochem. 1997 Jan;68(1):240-7. PubMed PMID: 8978731.
11: Bauer VJ, Duffy BJ, Hoffman D, Klioze SS, Kosley RW Jr, McFadden AR, Martin LL, Ong HH. Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. J Med Chem. 1976 Nov;19(11):1315-24. PubMed PMID: 1003409.
12: Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):940-8. PubMed PMID: 12183650.
13: Yenny, Nafrialdi, Djoerban Z, Setiabudy R. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Int J Clin Pharmacol Ther. 2011 Feb;49(2):162-8. PubMed PMID: 21255533.
14: Alabakovska SB, Labudović DD, Tosheska KN, Todorova BB. Low density lipoprotein particle size phenotyping in healthy persons and patients with myocardial infarction. Croat Med J. 2002 Jun;43(3):290-5. PubMed PMID: 12035134.